Evidence supporting the use of: DHA (Docosahexaenoic Acid)
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Docosahexaenoic acid (DHA), an omega-3 long-chain polyunsaturated fatty acid, has been investigated for its cardiovascular effects, including in patients with congestive heart failure (CHF). Scientific interest in DHA arises from epidemiological studies suggesting that diets rich in omega-3 fatty acids are associated with reduced cardiovascular events. Several clinical trials and meta-analyses have explored the impact of omega-3s, including DHA and EPA (eicosapentaenoic acid), on heart failure outcomes.

The evidence specifically supporting the use of DHA for treating or supporting CHF is limited and mixed. Some studies suggest that omega-3 supplementation may improve cardiac function, reduce inflammation, and lower hospitalization rates in CHF patients. For example, the GISSI-HF trial (2008) found modest benefits of omega-3 supplementation (EPA + DHA) in reducing mortality and hospital admissions in heart failure patients, though the effect size was small. Mechanistically, DHA may exert anti-inflammatory, anti-arrhythmic, and endothelial function–enhancing effects.

However, most studies use a combination of EPA and DHA, making it difficult to isolate the specific contribution of DHA. Guidelines (such as those from the American Heart Association) cite potential benefits but do not strongly recommend DHA supplementation as standard therapy for CHF. Overall, while there is some scientific basis for potential benefit, the evidence is not robust or unequivocal, and DHA should not replace established heart failure treatments.

More about DHA (Docosahexaenoic Acid)
More about Congestive Heart Failure

Products containing DHA (Docosahexaenoic Acid)

We currently have no products on Caring Sunshine that contain this ingredient.